Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

Connie L. Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, John F. Gerecitano, Paul A. Hamlin, Steve M. Horwitz, Erel Joffe, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, Colette Owens, Lia M. Palomba, David Straus, Gottfried von Keudell, Andrew D. ZelenetzVenkatraman E. Seshan, Stefano Luminari, Luigi Marcheselli, Massimo Federico, Anas Younes

Research output: Contribution to journalArticle

Abstract

Background: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. Methods: In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.

Original languageEnglish
Pages (from-to)78-90
Number of pages13
JournalEuropean Journal of Cancer
Volume126
DOIs
Publication statusPublished - Feb 2020

Fingerprint

Follicular Lymphoma
Disease Progression
Electrons
Positron-Emission Tomography
Survival
Tomography
Therapeutics
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide

Keywords

  • Early progression
  • Follicular lymphoma
  • PET
  • PFS24
  • R-CHOP

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. / Batlevi, Connie L.; Sha, Fushen; Alperovich, Anna; Ni, Ai; Smith, Katy; Ying, Zhitao; Gerecitano, John F.; Hamlin, Paul A.; Horwitz, Steve M.; Joffe, Erel; Kumar, Anita; Matasar, Matthew J.; Moskowitz, Alison J.; Moskowitz, Craig H.; Noy, Ariela; Owens, Colette; Palomba, Lia M.; Straus, David; von Keudell, Gottfried; Zelenetz, Andrew D.; Seshan, Venkatraman E.; Luminari, Stefano; Marcheselli, Luigi; Federico, Massimo; Younes, Anas.

In: European Journal of Cancer, Vol. 126, 02.2020, p. 78-90.

Research output: Contribution to journalArticle

Batlevi, CL, Sha, F, Alperovich, A, Ni, A, Smith, K, Ying, Z, Gerecitano, JF, Hamlin, PA, Horwitz, SM, Joffe, E, Kumar, A, Matasar, MJ, Moskowitz, AJ, Moskowitz, CH, Noy, A, Owens, C, Palomba, LM, Straus, D, von Keudell, G, Zelenetz, AD, Seshan, VE, Luminari, S, Marcheselli, L, Federico, M & Younes, A 2020, 'Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma', European Journal of Cancer, vol. 126, pp. 78-90. https://doi.org/10.1016/j.ejca.2019.12.006
Batlevi, Connie L. ; Sha, Fushen ; Alperovich, Anna ; Ni, Ai ; Smith, Katy ; Ying, Zhitao ; Gerecitano, John F. ; Hamlin, Paul A. ; Horwitz, Steve M. ; Joffe, Erel ; Kumar, Anita ; Matasar, Matthew J. ; Moskowitz, Alison J. ; Moskowitz, Craig H. ; Noy, Ariela ; Owens, Colette ; Palomba, Lia M. ; Straus, David ; von Keudell, Gottfried ; Zelenetz, Andrew D. ; Seshan, Venkatraman E. ; Luminari, Stefano ; Marcheselli, Luigi ; Federico, Massimo ; Younes, Anas. / Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. In: European Journal of Cancer. 2020 ; Vol. 126. pp. 78-90.
@article{578cc4f00f2349eeb5e062fef45e587b,
title = "Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma",
abstract = "Background: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. Methods: In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6{\%} for CT-staged patients compared with 70.6{\%} for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9{\%} and 100{\%} in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7{\%} versus 6.3{\%}, respectively), which was associated with a 9.7-fold higher risk of death. Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.",
keywords = "Early progression, Follicular lymphoma, PET, PFS24, R-CHOP",
author = "Batlevi, {Connie L.} and Fushen Sha and Anna Alperovich and Ai Ni and Katy Smith and Zhitao Ying and Gerecitano, {John F.} and Hamlin, {Paul A.} and Horwitz, {Steve M.} and Erel Joffe and Anita Kumar and Matasar, {Matthew J.} and Moskowitz, {Alison J.} and Moskowitz, {Craig H.} and Ariela Noy and Colette Owens and Palomba, {Lia M.} and David Straus and {von Keudell}, Gottfried and Zelenetz, {Andrew D.} and Seshan, {Venkatraman E.} and Stefano Luminari and Luigi Marcheselli and Massimo Federico and Anas Younes",
year = "2020",
month = "2",
doi = "10.1016/j.ejca.2019.12.006",
language = "English",
volume = "126",
pages = "78--90",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

AU - Batlevi, Connie L.

AU - Sha, Fushen

AU - Alperovich, Anna

AU - Ni, Ai

AU - Smith, Katy

AU - Ying, Zhitao

AU - Gerecitano, John F.

AU - Hamlin, Paul A.

AU - Horwitz, Steve M.

AU - Joffe, Erel

AU - Kumar, Anita

AU - Matasar, Matthew J.

AU - Moskowitz, Alison J.

AU - Moskowitz, Craig H.

AU - Noy, Ariela

AU - Owens, Colette

AU - Palomba, Lia M.

AU - Straus, David

AU - von Keudell, Gottfried

AU - Zelenetz, Andrew D.

AU - Seshan, Venkatraman E.

AU - Luminari, Stefano

AU - Marcheselli, Luigi

AU - Federico, Massimo

AU - Younes, Anas

PY - 2020/2

Y1 - 2020/2

N2 - Background: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. Methods: In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.

AB - Background: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. Methods: In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.

KW - Early progression

KW - Follicular lymphoma

KW - PET

KW - PFS24

KW - R-CHOP

UR - http://www.scopus.com/inward/record.url?scp=85077450213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077450213&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.12.006

DO - 10.1016/j.ejca.2019.12.006

M3 - Article

AN - SCOPUS:85077450213

VL - 126

SP - 78

EP - 90

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -